SARS-CoV-2 Mpro inhibitors from Siphonostegia chinensis: an integrated biophysical and computational study

来自中华管柱藻的SARS-CoV-2 Mpro抑制剂:一项综合生物物理和计算研究

阅读:1

Abstract

BACKGROUND: The COVID-19 pandemic caused by SARS-CoV-2 underscores the urgent need for novel antiviral agents. Preliminary screening indicated that the traditional Chinese medicine Siphonostegia chinensis Benth. (Bei Liu Ji Nu) possesses inhibitory activity against the SARS-CoV-2 main protease (Mpro), a key enzyme for viral replication. METHODS: To identify the active constituents responsible for its anti-SARS-CoV-2 activity, we employed an integrated strategy combining bio-layer interferometry (BLI) and ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS). RESULTS: Two phenolic compounds, verbascoside and 3,4-dicaffeoylquinic acid, were successfully fished out and identified from the ethanol extract as the most potent binders to Mpro. The binding affinities (KD) were determined to be 2.149 × 10(-6) M and 2.487 × 10(-5) M, respectively. Subsequent in vitro enzymatic inhibition assays confirmed their inhibitory effects, with IC(50) values of 0.076 µM and 0.194 µM, respectively. To elucidate the inhibition mechanism, molecular docking and molecular dynamics simulations were performed, revealing stable binding modes of both compounds within the catalytic pocket of Mpro through key interactions. Preliminary ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) predictions were also conducted to assess their drug-likeness. CONCLUSION: Our findings demonstrate that verbascoside and 3,4-dicaffeoylquinic acid exhibit high binding affinity and structural stability against SARS-CoV-2 Mpro, highlighting their potential as lead compounds for inhibiting viral replication. Furthermore, the comprehensive strategy established in this study provides a reliable and efficient approach for identifying bioactive components from complex herbal matrices, offering new perspectives and a scientific basis for the development of natural product-derived targeted therapeutics.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。